- Medical School - UT Health Science Center McGovern Medical School (1993-2000)
- Internship - Mayo Clinic (2000-2003), Internal Medicine
- Fellowship - Fred Hutchinson Cancer Research Center (2003-2006), Medical Oncology
Larry Anderson, M.D., Ph.D.
- Internal Medicine - Hematology/Oncology
- Myeloma Treatment
- Monoclonal Gammopathies
Larry Anderson Jr., M.D., Ph.D., is an Associate Professor in UT Southwestern Medical Center’s Department of Internal Medicine, Division of Hematology/Oncology. He joined the UT Southwestern faculty in 2008.
Dr. Anderson treats plasma cell disorders that include multiple myeloma, Waldenström's macroglobulinemia, amyloidosis, and other gammopathies. He specializes in treating these diseases with bone marrow transplantation.
In 2000, Dr. Anderson earned both a medical degree from the University of Texas Medical School at Houston and a doctoral degree in immunology from MD Anderson Cancer Center and the UT Graduate School of Biomedical Sciences/Health Science Center at Houston.
He completed an internship and residency in internal medicine at the Mayo Clinic’s Graduate School of Medicine, followed by a fellowship in medical oncology at the University of Washington Medical Center and Fred Hutchinson Cancer Research Center, where he later served as a research associate.
Dr. Anderson’s research interests include cancer immunology, immunotherapy, multiple myeloma, and stem cell transplantation. His research has been funded by the American Cancer Society, National Institutes of Health, American Society of Clinical Oncology, and the Multiple Myeloma Research Foundation.
Dr. Anderson is a member of the American Society of Hematology and the Texas Medical Association, and he is a Diplomate of both the American Board of Internal Medicine (ABIM) and the ABIM Subspecialty Board of Medical Oncology.
He was named a Texas Monthly Super Doctor in 2018.
Meet Dr. Anderson
Bone Marrow Transplant Specialist
Just a decade ago, patients diagnosed with multiple myeloma were expected to survive only a few years.
The good news is that today’s sophisticated therapies – delivered by experts like Larry Anderson Jr., M.D., Ph.D., at UT Southwestern Medical Center – are helping people with incurable bone marrow cancers like myeloma lead better, longer lives than ever before.
"We provide individualized treatments that consider each patient’s unique circumstances."
Dr. Anderson specializes in plasma cell cancers and bone marrow transplantation. The only oncologist in North Texas to exclusively treat plasma cell cancers, he sees about 90 percent of the myeloma patients who come to UT Southwestern.
He also cares for patients with similar diseases, including Waldenström's macroglobulinemia and amyloidosis.
“I like being able to provide treatments that extend people’s lives and give them a better quality of life, while also working to advance the field by participating in clinical trials that help to develop new treatments,” Dr. Anderson says.
With the current treatments for myeloma, experts estimate the average survival is now eight to 10 years, Dr. Anderson explains. And the latest FDA-approved treatments are more effective and more manageable than traditional chemotherapy.
“It’s been very rewarding to witness the dramatically improved outcomes in my patients over the past several years as new therapies have become available,” Dr. Anderson says.
In addition to offering patients the most innovative therapies and a range of clinical trials for plasma cell disorders, UT Southwestern delivers comprehensive, highly specialized care.
“Having a doctor who sees patients with conditions like theirs exclusively – from their first visit and diagnosis through transplant and long-term follow up – can be a big advantage over seeing a general oncologist who may have only a few myeloma patients,” Dr. Anderson says.
Dr. Anderson is also happy to see plasma cell disorder patients for second opinions to help with guiding treatment decisions, getting them on new therapies on clinical trials, or just for their stem cell transplant process, after which they can return to their referring oncologist if they like.
A number of promising new treatments for plasma cell cancers are currently in clinical trials, Dr. Anderson notes, and UT Southwestern hopes to continue adding more to the list.
"We do the best we can to give patients high-quality lives that are as long as possible,” he says.
- American Society of Hematology
- D Magazine Best Doctor 2021
- ACS Institutional Research Grant 2010, Research Grant
- ASCO Young Investigator Award 2006, Research Grant
- K12 Career Development Award 2006, Research Grant
- Multiple Myeloma Research Foundation Fellow Award 2006, Research Grant
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, de Boer C, Hoehn D, Lin TS, Richardson PG, Blood 2020 08 136 8 936-945
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Germans SK, Kulak O, Koduru P, Oliver D, Gagan J, Patel P, Anderson LD, Fuda FS, Chen W, Jaso JM, American journal of clinical pathology 2020 11 154 6 816-827
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Grosicki S, Simonova M, Spicka I, Pour L, Kriachok I, Gavriatopoulou M, Pylypenko H, Auner HW, Leleu X, Doronin V, Usenko G, Bahlis NJ, Hajek R, Benjamin R, Dolai TK, Sinha DK, Venner CP, Garg M, Gironella M, Jurczyszyn A, Robak P, Galli M, Wallington-Beddoe C, Radinoff A, Salogub G, Stevens DA, Basu S, Liberati AM, Quach H, Goranova-Marinova VS, Bila J, Katodritou E, Oliynyk H, Korenkova S, Kumar J, Jagannath S, Moreau P, Levy M, White D, Gatt ME, Facon T, Mateos MV, Cavo M, Reece D, Anderson LD, Saint-Martin JR, Jeha J, Joshi AA, Chai Y, Li L, Peddagali V, Arazy M, Shah J, Shacham S, Kauffman MG, Dimopoulos MA, Richardson PG, Delimpasi S, Lancet (London, England) 2020 11 396 10262 1563-1573
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Chari A, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Lunning M, Usmani SZ, Anderson LD, Chhabra S, Girnius S, Shustik C, Stuart R, Lee Y, Salman Z, Liu E, Valent J, Hematological oncology 2020 Aug 38 3 353-362
Generation of T-cells reactive against CT-7 and BCMA peptides: Potential targets for T-cell immunotherapy of multiple myeloma.
Anderson LD, Maloney DG, Riddell SR Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Jun 24 18_suppl 7615
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse.
Dimopoulos M, Weisel K, Moreau P, Anderson LD, White D, San-Miguel J, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Casal E, Srinivasan S, Yu X, Nguyen TV, Biyukov T, Peluso T, Richardson P, Leukemia 2020 Sep
Nonmyeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory Waldenstrom macroglobulinemia: Evidence for a graft-versus-lymphoma effect.
Maffini E, Anderson LD, Sandmaier BM, Green DJ, Storer BE, Niederwieser D, Maziarz RT, Maloney DG, Storb R Haematologica 2018 Mar
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J, The New England journal of medicine 2021 02 384 8 705-716
The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement.
Bergstrom CP, Dahiya S, Chen W, Zhang CC, Zhu H, Yan J, Madanat Y, Patel P, Vusirkala M, Ramakrishnan P, Rizvi S, Chung S, Awan F, Anderson LD, Collins R, Kansagra A, Leukemia research 2020 Nov 100 106480
Adoptive T-cell therapy for B-cell malignancies.
Hudecek M, Anderson LD, Nishida T, Riddell SR Expert review of hematology 2009 Oct 2 5 517-32
DNA Immunization Against Amyloid beta 42 has High Potential as Safe Therapy for Alzheimer's Disease as it Diminishes Antigen-Specific Th1 and Th17 Cell Proliferation.
Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Stüve O, Eagar TN, Rosenberg RN Cellular and molecular neurobiology 2011 Aug 31 6 867-74
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma.
Anderson LD, Cook DR, Yamamoto TN, Berger C, Maloney DG, Riddell SR Cancer immunology, immunotherapy : CII 2011 Jul 60 7 985-97
Successful treatment of relapsed and refractory extramedullary acute promyelocytic leukemia with tamibarotene.
Naina HV, Levitt D, Vusirikala M, Anderson LD, Scaglioni PP, Kirk A, Collins RH Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Jun 29 18 e534-6
A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aß42 DNA vaccine for Alzheimer disease.
Lambracht-Washington D, Qu BX, Fu M, Anderson LD, Eagar TN, Stüve O, Rosenberg RN Journal of neuroimmunology 2013 Jan 254 1-2 63-8
Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma.
Halm EA, Anderson LD, Gerber DE Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Jan JCO2016704726
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Chari A, Larson S, Holkova B, Cornell RF, Gasparetto C, Karanes C, Matous JV, Niesvizky R, Valent J, Lunning M, Usmani SZ, Anderson LD, Chang L, Lee Y, Pak Y, Salman Z, Graef T, Bilotti E, Chhabra S Leukemia & lymphoma 2018 Apr 1-7
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Anderson LD, Sutherland HJ, Yong K, Hoos A, Gorczyca MM, Lahiri S, He Z, Austin DJ, Opalinska JB, Cohen AD The Lancet. Oncology 2018 Dec 19 12 1641-1653
Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.
Richardson PG, Bensinger WI, Huff CA, Costello CL, Lendvai N, Berdeja JG, Anderson LD, Siegel DS, Lebovic D, Jagannath S, Laubach JP, Stockerl-Goldstein KE, Kwei L, Clow F, Elias L, Salman Z, Graef T, Bilotti E, Vij R British journal of haematology 2018 Mar 180 6 821-830
Bleeding due to acquired dysfibrinogenemia as the initial presentation of multiple myeloma.
Siddiq N, Bergstrom C, Anderson LD, Nagalla S, BMJ case reports 2019 Jul 12 7
Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of Multiple Myeloma
Anderson LD Jr, Cook DR, Yamamoto T, Berger C, Maloney DG, and Riddell SR Cancer Immunology Immunotherapy 2011 (In Press)
Bone marrow transplant conditioning intensified with liposomal clodronate to eliminate residual host antigen presenting cells fails to ameliorate graft-versus-host disease and increases peri-BMT mortality.
Everse LA, Anderson LD Jr, Rooijen N van, and Mullen CA Transplantation March 2001 71 611-618
Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenstrom s Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.
Anderson LD Jr, Sandmaier BM, Maris MB, et al Blood November 2006 108 Abstract #3034
Use of Gene-Modified T-cells as Antigen Presenting Cells (T-APC) for Vaccination against Myeloma Antigens.
Anderson LD Jr, Cook DR, Berger C, Maloney D, and Riddell SR Blood November 2007 110 Abstract #2758
Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD Jr, Mori S, Mann S, Savary CA, and Mullen CA Cancer Research October 2000 60 5797-5802
Ganciclovir chemoablation of herpes simplex thymidine kinase suicide gene-modified tumors produces tumor necroses and induces systemic immune responses.
Mullen CA, Anderson L, Woods K, Nishino M, and Petropoulos D Human Gene Therapy September 1998 1998 2019-2030
Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine
Anderson LD Jr, Petropoulos D, Everse LA, and Mullen CA Cancer Research October 1999 59 1525-1530
HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells.
Anderson LD Jr, Hudson JM, Savary CA, Fisk B, Gershenson DM, and Ioannides CG Cancer Immunology Immunotherapy October 1999 48 401-410
Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease
Anderson LD Jr, Savary CA, and CA Mullen Blood April 2000 95 2426-2433
DNA Immunization against the cerebral self antigen Amyloid beta 42 has high potential as safe therapy for Alzheimer’s Disease
Lambracht-Washington D, Qu B, Fu M, Anderson LD Jr, Stuve O, Eager TN, and Rosenberg RN Cellular and Molecular Neurobiology 2011 (In Press)
Adoptive T-cell therapy for B-cell malignancies
Hudecek M, Anderson LD Jr, Nishida T, and Riddell SR Expert Review of Hematology 2009 2 517-532
- Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
- Stem Cell Transplantation
- Multiple Myeloma
- MAGE-C1 (CT-7)
- Cancer immunology
- Myeloma Treatment
- Monoclonal Gammopathies
- Waldenström Macroglobulinemia
- Monoclonal Gammopathies of Unknown Significance (MGUS)
- Malignant Hematology
- Bone Marrow Transplant
Q&A by Dr. Anderson
Results: 1 Locations
Dallas, Texas 75390 214-645-4673